Endo Withdraws Opana Painkiller From Market at FDA’s Request Post author:Sam Post published:July 6, 2017 Post category:Drug Industry Daily Endo will withdraw Opana ER from the market, following an FDA request in June. Source: Drug Industry Daily You Might Also Like Merck’s Lynparza Flops in Phase 3 Colorectal Cancer Study July 19, 2022 Accelerated Approval Drugs Stay on Market for Years Without Showing Benefit, HHS Reports October 2, 2022 Florida Drugmaker Draws FDA Warning for Repackaging, Distribution May 8, 2018
Accelerated Approval Drugs Stay on Market for Years Without Showing Benefit, HHS Reports October 2, 2022